Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiometabolic risk reduction with rimonabant in daily practice
2006-001404-37Phase 4Completed
- Sponsor
- Maastricht University
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rimonabant in type 2 diabetes mellitus (T2DM), impaired fasting glucose (IFG), Abdominal adiposity (ABCD) and 1 more, sponsored by Maastricht University. Primary endpoints: Waist circumference at 12 months, Plasma glucose at 12 months and 2 more. Started Jul 2006; status: completed.
02
Drugs
rimonabant
03
Conditions
type 2 diabetes mellitus (T2DM)impaired fasting glucose (IFG)Abdominal adiposity (ABCD)cardiometabolic disease
Beyond the preview
Go deeper on 2006-001404-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001404-37.